Lymph node (LN) infiltration by neoplastic process involves important changes in lymph node immune microenvironment. In particular, regulatory T cells (Treg) seem to have a key role in altering the immunoediting function of the immune system which leads to the elusion of the tumor from immune surveillance. In this study, we evaluate the expression of T-cell markers in CD4+ and CD8+subsets from tumor-positive and tumor-negative lymph nodes from the same, advanced stage breast cancer patient.
(CD25) and CD45RO are increased in CD4 and CD8 cells from tumor-positive lymph nodes. Immune profiling of lymph nodes became of increasing interest with the appearance of the sentinel node concept, the assessment of the first, closest lymph node to the original tumor. This analysis is used mostly in breast cancer and melanoma patients, and predicts survival significantly (3) and also reduces the need for complete axillary lymphadenectomy (4) . Recent literature data suggest that T cells contribute to cancer metastasis, and especially CD25+FoxP3+ T regulatory (Treg) cells, which are known to increase in number in lymph nodes as well as in the original tumors.. They inhibit activated T-helper cells and facilitate neoplastic processes to elude immune surveillance, rather than eliminating and limiting tumor development and progression (5) . Transcription factor FoxP3 is characteristic also for Tregs in CD4 and CD8, and T cells expressing Foxp3 are correlated with primary tumor size but not with lymph node invasion or other clinical parameters (6) . Hence, it is reasonable to consider a therapeutic approach targeted against Tregs in cancer. In addition to FoxP3 which is intracellular, there are various markers which are differently expressed on CD4 Treg cells like CD25, GITR (glucorticoid-induced tumor necrosis factor-related, also called TNFRSF 18 or CD357), CTLA-4 (Cytotoxic T lymphocyte antigen-4 or CD152) and CD127. GITR is expressed on various immune cells, and is upregulated upon activation (7) (8) (9) leading to increased T helper activity and Treg proliferation which leads to decreased Treg suppression (10, 11) . GITR acts as costimulatory agent (12, 13) and is involved in autoimmune, inflammatory and antitumoral immune response (14, 15) . There is a considerable difference between murine and human GITR (hGITR). hGITR has been less investigated, and is less expressed in effector T cells, but is markedly increased upon their activation (16) . GITR is expressed on human CD4+CD25+FoxP3+ Treg cells (17) .
In this study, in order to analyze the immune background ofLN infiltration, we assessed CD4+ and CD8+ cells deriving from lymph nodes of advanced stage cancer patients. We propose a profiling pattern of lymph node-derived CD4+ T cells in breast cancer patients, and we demonstrate the increase of two distinct Treg populations in tumor positive vs tumor negative lymph nodes deriving from the same patient.
MATERIALS AND METHODS

Lymphocytes
Three patients with advanced (stage III) breast cancer, who underwent surgery at the "Ion Chiricuta" Oncologic Institute Cluj-Napoca, without any prior treatment were enrolled in the study, after giving informed consent according to the "Iuliu Hatieganu" University of Medicine and Pharmacy Ethics Committee regulations and European Union legislation. During surgery, after extirpation of axillary non-sentinel lymph nodes (non-SLN), each node was cut in half, and pathological examination took place in parallel with cell separation and study. A total of 3 tumor-positive and 3 tumor-negative lymph nodes were assessed, one pair from each patient. Cells were immediately processed in each experiment, without freezing or other procedures. Lymphocytes were extracted using 40 urn mesh cell strainers (Becton Dickinson) in sterile conditions under laminar flow cabinet. Ex-vivo lymphocytes were consecutively counted and used for magnetic cell separation, flowcytometry and RNA extraction.
Magnetic cell separation
Lymphocytes were counted by hemocytometer and consecutively separated in positive using Miltenyi CD4 and CD8 microbeads (Miltenyi Biotec, Germany) according to the manufacturer's instructions. Ice-cold 0.5% FCS in PBS was used as separation buffer. Midi and miniMACS magnets and LS and MS columns were used according to total cell number. Two consecutive passages were used through new columns in order to enhance cell population purity, which resulted 97-98%.
Flowcytometry -antibodies
Anti-CD25-FITC and APC, anti-GITR-PE, anti-CD28-FITC, anti-CDl27-APC, anti-CD62L-FITC, anti-CD45RA-FITC, anti-CD45RO-APC, and anti-FoxP3-APC were purchased from Miltenyi Biotec. Anti-GITRL-PE antibody was purchased from R&D Systems. Matching isotype controls were purchased and used in all stainings as controls for each antibody, recommended by both manufacturing companies (Miltenyi Biotec and R&D). Except for FoxP3 staining, prewashed cells were incubated in excess antibody at 4°C for 30 minutes, then washed and resuspended in PBS 1%FCS. For FoxP3 staining Intracellular Buffer Set from Miltenyi Biotec was used according to the manufacturer's indications. Simple, double and triple colorations were used, and flowcytometric acquisition was carried out on a FACSCalibur flowcytometer (Becton Dickinson). All presented markers and quadrants on ·the graphs were set according to the corresponding isotype contro ls. Data was analyzed using FCS Express V3 software. Student's t-test was used for statistical analysis . (*:t' * p<O.OOI, **p<O.OI)
Gating strategy for CD4 +cells
We used several markers in an attempt to identify certain subpopulations of cells. CD25 and GITR are markers of Treg, but also markers of activated T cells, but usually activated effectors exhibit low amounts of these receptors .
It is generally accepted that CD25-cells are naive effectors. CD 127 is also an effector marker, and is downregulated in Treg cells (18, 19) . A subtype of CD25!owGITWCDl27+ Treg was recently identified and characterized (16, 20) . According to this data we identified a gating strategy based on CD25, GITR and CD 127 in an attempt to identify 3 subpopulations: effectors, CD25highGITWCDI27-/low and CD25 IowGITR +CDI27' Treg cells.
RNA extraction, eDNA synthesis and PCR
Trizol LS reagent (Invitrogen ) was used, followed by cDNA synthesis using iScript reverse transcriptase (Biorad). Semi-quantitative conventional PCR was used to amplify GIT RL from CD8 cells, using the following primers: 5'-CTT TAA GCC ATT CAA GAA CTC A-3' and 5'-CCC AAC ATG CAA TTC ATA AGT CC-3' . The number of cycles was established in such a way that reactions remained in logarithmic phase and the PCR was not saturated. Those conditions offered a "yes or no" type result using a cut-off to eliminate weak signa ls, (e.g. we did not obtain PCR products from PBMC cells): first cycle 7 min 95°C, 40 sec 55°C, I min n oc, followed by 30 cycles of 30 sec 95°C, 40 sec 55°C, I min n oc, using Taq Gold (Invitrogen).
RESULTS
Phenotypic analysis ofCD4lymphocytesfrom lymph nodes ofbreast cancer patients
CD4+ cells were isolated using magnetic separatio n technique from tumor positive and tumor negative lymph nodes from each breast cancer patient. Cells were characterized by labeling them with CD25, GITR, CDl27 and FoxP3 as Treg markers and CD 154, CD28 and CD62L as activation markers , and also CD45RA, and CD45RO as naive responder and memory cell markers , respectively. We also assessed GITRL (GITR ligand). Results are expressed as mean percentage with standard deviation (Fig. 1 ).
CD4+ lymphocytes of positive lymph nodes presented significantly higher levels of the following markers : CD25, GITR, CD28, FoxP3, while decrease d levels were observed for CD45RO, and no expression was found for GITRL.
Phenotypic analysis ofCD8 lymphocytesfrom lymph nodes ofbreast cancer patients CD8 cells resulting from magnetic separation were characterized by labeling them with CD25, GITR, CDl27, FoxP3, CD62L, CD45RA, CD45RO, CD28 and GITRL (Fig. 2) .
CD8 cells deriving from positive nodes expressed more CD25, CD45RO and less CD45RA. The rest . of the studied markers did not present statistically significant changes (Fig. 2) . We have found small amounts of GITRL expressed in all 3 pairs of lymph nodes, with relatively increased levels in the CD8 cells from the positive nodes. Since no previous study reported GITRL expression in human CD8 cells, we confirmed this expression also at RNA level performing semi-quantitat ive conventional PCR (data not shown).
Since except for the expression patterns of CD25 and CD45 there were no significant differences in the CD8+population; we directed our attention towards the CD4 population , where more differences were found. In particular, we addressed the analysis of the CD4+Treg population.
Analy sis ofthe CD4+Treg population
Since CD25/CD127 and CD25/GITR stammg have been recently used to identify Treg subsets (18, 19) , we stained cells with CD25, CD127 and GITR in the attempt to verify whether Treg cells appear to be present in a higher number in tumor-positive lymph nodes compared to tumor-negative lymph nodes (Fig. 3) .
CD2s+CD127-now population (gate Rl ) was increased almost three-fold in CD4+ cells from the tumor-positive lymph nodes compared to those from tumor-negative lymph nodes (Fig. 3) . A similar result was seen with CD25 10wCD 127+ cells (gate R2).
Next we analyzed the GITR expression in the populations defined by gate RO, Rl , R2 (Fig. 4) .
As expected, gate RO representing CD25-naive T cells completely lack GITR expression, and Rl defining the classical CD25 high Treg population is 100% GITR positive . GITR+population is distributed in the R1Treg region , but also in the R2 region. GITR+ cells inside gate R2 are CD25 IowGITR +CD127+ cells and can be considered a subset ofTreg cells according to the latest development in Treg subpopulations (16, 20) . Therefore, we evaluated the number of GITR+ cells inside gate R2 in tumor-positive and tumor-negative lymph nodes and found that also CD25 IowGITR +CD127+ cells are dramatically increased in tumor-positive lymph nodes (Fig. 5 ).
DISCUSSION
Despite all the efforts and the important results obtained in the field, breast cancer is still a major health problem. An important amount of data is available on lymph node metastasis and its role in disease progression and survival prognostics. One recent development is that both CD4 and CD8 Tregs are involved in disease progression and evolution, inhibiting effective T responder activity and contributing to the escape ofthe tumor from immune surveillance. The immunoediting function ofa breast tumor patient is dysfunctional (21) . In this study we aim to shed light on the immune background of non-SLN metastasis. We used this comparison between positive and negative nodes deriving from the same patient for the first time, and we investigated advanced stage cancer in order to see the differences in two local microenvironments of the same immune system. Since Tregs are proven to participate in the metastatic process (5) we investigated the presence of Tregs in LN and compared the LN+with the LN. The most mentioned marker whose expression seems to promote metastasis is FoxP3, the level of which is increased in tumor infiltrating lymphocytes , peripheral blood and which is a negative prognosis factor in these locations. In sentinel nodes examined in early stage cancer, FoxP3 expression also predicts non-Sl.N metastasis (22) . In the non-SLN of advanced cancer studied in our experiments FoxP3 was increased in the CD4 population of LN+ in comparison with the LN-, but we found a relatively small amount of FoxP3 in both CD4 and CD8 cells compared to CD25 and GITR. In fact, FoxP3 expression can be reduced or downregulated by various triggers. FoxP3+populations elicit instability in certain conditions, lose their Treg activity, and exhibit responder function and phenotype. On the other hand, not all Tregs express FoxP3, and FoxP3 expression is not always associated to Treg activity.
In both CD4 and CD8 cells we found an increase of CD25, which is a Treg marker, but also a marker of activated T cells. CD127, which correlates inversely with Treg activity, may be used to identify Treg cells (18, 19) . Another important Treg and activated T-cell marker is GITR (9, 23) which correlates with CD25 expression. Recently, a novel CD4 Treg population was described and characterized, which is CD25 IowGITR+ CD127+ and exerts suppressor activity (16, 20) . We used CD25, GITR and CD 127 to analyze CD4 T-cell subsets (Fig.  3) , and found that both CD25 highGITR+CDl27and CD25 1owGITR+CD127+ Treg subsets are significantly increased in LN+ compared to the LN-of the same patient. We also found less responder cells in the LN+.
The lack of appropriate control is a problem in LN analysis. It is unethical to take healthy LN from patients, and comparison with peripheral blood or even lymph nodes from benign pathology can be deceiving and irrelevant. This is the reason why we worked with LN of different immunological status from the same patient (but analyzed in the same kinetic moment). However, in benign diseases lymph nodes also contain functional CD4 Tregs, which express CD45RO, CD62L, CTLA-4. Bianchini et al. found 0.79% (main percentage) of CD25 IowGITWCD127+ cells in peripheral blood of healthy donors and showed that these cells exert strong suppressive activity (16) . To our knowledge, this is the first study identifying CD25 IowGITR+CD127+ Treg subset in breast cancer. We found 7.1% in the LN-, 18.4% in the LN" suggesting a concentration of Tregs in the LN+ with functional relevance in metastasis. The fact, that anti-GITR antibody inhibits GITR+ Treg suppressive activity makes this subset a possible target of anti-Treg adjuvant therapy in cancer. Much less is known of the CD8 Treg population. Recently identified populations include: CD8+CD25+GITR+ cells which are to be found mostly at tumor sites and inhibit CD8 and CD4 naive responders; alloantigenspecific CD28-Tregs; yoTCR which do not express CD25 and FoxP3 and contribute to tumor transformation; and also a Natural Killer regulatory cell. In our experiments CD25 was increased, but GITR and FoxP3 was comparable in the positive and negative node-derived CD8 cells. CD45RO expression on the other hand was increased, and this is consistent with the Treg phenotype of the CD8 lymphocytes and correlated with the increase ofCD25.
In the CD8 population, we identified the expression of a small amount of GITRL. GITRL is expressed usually on antigen presenting cells (APC) like macrophages, dendritic cells and B cells especially upon activation (24, 25) . On resting T cells the results are contradictory. Murine CD8 express small amounts of GITRL (12) . Other authors did not find any GITRL on murine T cells (13) . On activated murine CD8 lymphocytes GITRL is upregulated (10, 12) . To our knowledge the present results are the first data on human lymph nodes concerning GITRL. Since it is proven that GITRL can activate indoleamine 2,3-dioxygenase (26) synthesis by interaction with GITR and reverse signaling (27) and that IDO can convert human CD4+CD25-(responder) cells to CD4+CD25+FoxP3+ Tregs (26) , it may be a GITRL-mediated pathway of responder-into-Treg shift or an IL-10 mediated inhibition of host immune response (28, 29) which contributes to the change of local and distal microenvironment. This is also a possible key point in intervention on the GITR/GITRL system, since hGITR-Fc is able to stimulate GITRL-. dependent reverse signaling and probably also inhibits GITR triggering by its ligand (29, 30) . To this end an inhibitory molecule must be found to block GITRL and/or a safe agonist for GITR triggering. In this manner blocking potential pro-Treg action of GITRL could be stopped, and suppressive activity of existent Tregs may be reduced by GITR triggering.
In conclusion, we found a different immune profile in LN-derived ex vivo lymphocytes, using a gating model which is applicable to any other source of lymphocytes with the use of GITR expression as a key factor in distinguishing three essential CD4+ subpopulations: responders, CD 127lowCD25highGITR+ and CD127highCD251owGITR+ Tregs. The latter two populations are increased in the tumor-positive nodes. In addition, we performed a CD8 profiling and identified increased CD25 and CD45RO expression and also a low level of GITRL expression, which increases in the tumor-positive node-derived CD8 cells, which may be another possible parameter in the tumor positive lymph node immune microenvironment. This is intended to contribute to a better understanding of the immune background of metastasis in lymph nodes of cancer patients, since most studies are targeting tumor infiltrating lymphocytes and PBMC.
